GPX4 and cancer: For instance, commonly used inducers like RSL3 and Erastin act by directly inhibiting GPX4 and SLC7A11, respectively, but they fail to comprehensively modulate cancer-associated signaling networks (Shin et al., 2018; Kain et al., 2020).